Business context and reporting period
Repro Med Systems, Inc. (the registrant named in the filing) designs, manufactures and markets medical devices, including the FREEDOM60 infusion system, HIgH-Flo needle sets and RES-Q-VAC suction products. This unaudited Form 10-Q covers the three and six months ended August 31, 2015; comparisons are with the corresponding 2014 periods.
Financial performance and condition
| Metric | Three months ended Aug. 31, 2015 | Six months ended Aug. 31, 2015 |
|---|---|---|
| Net sales | $3.17 million; up 26.4% | $5.80 million; up 12.7% |
| Gross profit / margin | $2.01 million / 63.4% (65.3% prior year) | $3.52 million / 60.8% (61.5% prior year) |
| Operating profit | $506,781 (prior year $319,064) | $427,917 (prior year $560,163) |
| Net income | $335,214 (prior year $202,994) | $270,574 (prior year $361,050) |
| Net margin | 10.6% (prior year 8.1%) | 4.7% (prior year 7.0%) |
| Operating cash flow | $704,232 for six months (prior year $219,996) |
For the six-month period, investing cash outflow was $104,447 and financing cash flow was zero; cash increased $599,785 to $3.16 million. At August 31, cash and cash equivalents were $3.16 million, certificates of deposit were $259,789, current assets were $6.38 million and current liabilities were $852,053. Total liabilities were $1.15 million; the balance sheet reports no borrowings or interest expense for the 2015 period.
Changes versus the prior comparable period
Quarterly sales growth was driven mainly by domestic infusion-product sales, which rose 28.8%; international sales rose 15.4%. For the six months, international sales rose 31.2% and domestic sales 9.0%. Six-month net income declined 25.1% despite higher sales, as selling, general and administrative (SG&A) expense increased 31.5% to $2.87 million. The increase included approximately $0.2 million in severance, $0.2 million in higher salaries, $0.1 million in recruiting and consulting, and $0.2 million in legal fees, mainly related to patent litigation. Research and development expense fell 68.1% to $92,376, largely due to reduced outside consulting and department attrition.
Gross margin declined in both reported comparisons. Management attributed the pressure mainly to lean-manufacturing consulting and production-equipment repairs, maintenance and validation costs incurred in the quarter. Operating cash flow improved year over year, helped by lower inventory investment, reduced receivables and higher payables and accrued expenses; prior-year operating cash flow had been affected by a substantial inventory increase.
Outlook, risks and notable items
Management said cash on hand and expected operating cash generation should fund operations, research and development, and capital expenditures for the next 12 months. It anticipated gross-margin improvement in the remaining six months of the fiscal year from lean-manufacturing efforts, citing early capacity gains and lower assembly labor costs. This is management’s expectation, not a quantified forecast. The company also described continued opportunities for FREEDOM60 in subcutaneous immunoglobulin and other infusion applications; FreedomEdge had begun shipping for product evaluation.
Risks identified include FDA and other regulatory requirements, product acceptance and competition, reimbursement and home-health-care regulation, market expansion, R&D outcomes, patent enforcement, capital availability and dependence on key personnel. Patent disputes with a competitor remain ongoing: a June 2015 preliminary injunction restricts certain company statements about competitor products, and the competitor filed a separate infringement case. The company sought patent reexamination and inter partes review; outcomes were uncertain.
After quarter-end, on September 30, 2015, the board authorized open-market repurchases of up to 1,000,000 shares and approved a stock-option plan covering up to 2,000,000 shares, subject to shareholder approval. The filing reported no material subsequent events requiring disclosure other than these items.
Important facts for investors to verify
- Whether sales growth and management’s anticipated margin recovery continue, and whether lean initiatives deliver sustained savings.
- Whether elevated SG&A, particularly legal, staffing and reorganization costs, persists and affects profitability.
- Developments and potential financial or commercial effects of the competitor patent litigation and related review requests.
- Actual execution and funding of the authorized share repurchase, and shareholder approval and use of the new option plan.
- Product adoption and regulatory or market developments, including FreedomEdge evaluations and demand for infusion products.